Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90yttrium anti-CD20 monoclonal antibody.

被引：0
|
作者：
Wiseman, G
Witzig, T
White, CA
Solinger, A
Gordon, L
Raubitschek, A
Emmanouilides, C
Gutheil, J
Parker, E
Chinn, P
Grillo-Lopez, A
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Sidney Kimmel Canc Ctr, San Diego, CA USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 1998年 / 13卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [21] Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody (MAB) in relapsed non-Hodgkin's lymphoma (NHL):: Dosimetry and radioimmunotherapy (RIT).
    Scheidhauer, K
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Wolf, I
    Reidel, G
    Peschel, C
    Schwaiger, M
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 268P - 268P
  • [22] Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
    Yuen, Sam
    Phillips, Tycel J.
    Bannerji, Rajat
    Marlton, Paula
    Gritti, Giuseppe
    Seymour, John F.
    Johnston, Anna
    Arthur, Christopher
    Dodero, Anna
    Sharma, Sunil
    Hirata, Jamie
    Musick, Lisa
    Flowers, Christopher R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1281 - 1289
  • [23] IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with pretreated low-grade non-Hodgkin's lymphoma.
    Schwandt, KU
    Bremer, K
    ANNALS OF ONCOLOGY, 2000, 11 : 105 - 105
  • [24] Phase I/II radioimmunotherapy trial with 90Y-labeled epratuzumab (LymphoCide™ anti-CD22 monoclonal antibody) in relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Hajjar, G
    Burton, JD
    Sharkey, RM
    Schuster, SL
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, E
    Leonard, JP
    Coleman, M
    Goldenberg, DM
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 156P - 156P
  • [25] Application of monoclonal anti-CD20 antibody rituximab in the treatment. of non-Hodgkin's lymphoma
    Mihaljevic, Biljana
    Jankovic, Snezana
    Jakovic, Ljubomir
    Jovanovic, Maja Perunicic
    Andelic, Bosko
    Milosevic, Violeta
    Sretenovic, Aleksandra
    Virijevic, Marjana
    Petrovic, Milan
    VOJNOSANITETSKI PREGLED, 2008, 65 (03) : 229 - 233
  • [26] Radioimmunotherapy (RIT) of refractory or relapsed Hodgkin's lymphoma with 90Yttrium-labeled antiferritin antibody.
    Decaudin, D.
    Kadouche, J.
    Levy, R.
    Belhamiche, M.
    Arnaud, P.
    Alberini, J. L.
    Lokiec, F. M.
    Pecking, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 108S - 108S
  • [27] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Klemens Scheidhauer
    Ingo Wolf
    Hans-Joachim Baumgartl
    Christoph von Schilling
    Burkhard Schmidt
    Günther Reidel
    Christian Peschel
    Markus Schwaiger
    European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29 : 1276 - 1282
  • [28] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Scheidhauer, K
    Wolf, I
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Reidel, G
    Peschel, C
    Schwaiger, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (10) : 1276 - 1282
  • [29] Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma
    Alcindor T.
    Witzig T.E.
    Current Treatment Options in Oncology, 2002, 3 (4) : 275 - 282
  • [30] Radiolabelling and quality control of anti-CD20 antibody-rituximab with 90Yttrium for the treatment of relapsed and refractory large B-cell NHL
    Thakral, P.
    Malhotra, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S301 - S301
12345